NCT01966614View on ClinicalTrials.gov

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

PHASE3CompletedINTERVENTIONAL
Enrollment

479

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

PRX302

Single intraprostatic bilateral injection at a dose of 0.6 µg/g

OTHER

Placebo

Single intraprostatic bilateral injection of vehicle only

Trial Locations (76)

3050

Parkville

3140

Tauranga

3194

Mentone

5011

Woodville South

5041

Daw Park

8013

Christchurch

10016

New York

10457

The Bronx

11530

Garden City

12550

Newburgh

12601

Poughkeepsie

14034

Chernihiv

19004

Bala-Cynwyd

19010

Bryn Mawr

20770

Greenbelt

21204

Baltimore

Towson

21237

Baltimore

27612

Raleigh

28025

Concord

29572

Myrtle Beach

29650

Greer

33060

Pompano Beach

33134

Coral Gables

33180

Aventura

33449

Wellington

33770

St. Petersburg

35801

Huntsville

47130

Jeffersonville

49005

Dnipropetrovsk

50266

West Des Moines

58000

Chernivtsi

59808

Missoula

61000

Kharkiv

62701

Springfield

69600

Zaporizhzhya

75010

Carrollton

75390

Dallas

77030

Houston

79013

Lviv

79059

Lviv

80220

Denver

83642

Meridian

83814

Coeur d'Alene

84124

Salt Lake City

87109

Albuquerque

90017

Los Angeles

90806

Long Beach

91356

Tarzana

92120

San Diego

92123

San Diego

92653

Laguna Hills

92660

Newport Beach

98166

Burien

99503

Anchorage

119991

Moscow

125206

Moscow

153040

Ivanovo

194044

Saint Petersburg

194354

Saint Petersburg

197022

Saint Petersburg

197136

Saint Petersburg

197374

Saint Petersburg

198205

Saint Petersburg

199178

Saint Petersburg

344011

Rostov-on-Don

410012

Saratov

06762

Middlebury

02445

Brookline

08054

Mount Laurel

L6T 4S5

Brampton

N2N 2B9

Kitchener

L6H 3P1

Oakville

0145

Whau Valley

02125

Kyiv

04053

Kyiv

All Listed Sponsors
lead

Sophiris Bio Corp

INDUSTRY

NCT01966614 - Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH | Biotech Hunter | Biotech Hunter